Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CVS HEALTH CorpCVS · Entity 2884 | EVP&President-PharmacyServices | August 03, 2022 | August 05, 2022 |
| PROKIDNEY CORP.PROK · Entity 5181 | Director | May 28, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CVS HEALTH Corp
Report date August 03, 2022 · Filed August 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 109,183.3689 |
Ending reported balance
After 2022-08-04 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2022-08-03 · Exercise / conversion · Acquired 70,398 · Balance 179,581.3689 Row 2 · 2022-08-03 · Sale · Disposed 70,398 · Balance 109,183.3689 F1: All sales were effected pursuant to a Rule 10b5-1 plan. Row 3 · 2022-08-03 · Exercise / conversion · Acquired 50,501 · Balance 159,684.3689 Row 4 · 2022-08-03 · Sale · Disposed 50,501 · Balance 109,183.3689 F1: All sales were effected pursuant to a Rule 10b5-1 plan. Row 5 · 2022-08-04 · Exercise / conversion · Acquired 22,541 · Balance 131,724.3689 Row 6 · 2022-08-04 · Sale · Disposed 22,541 · Balance 109,183.3689 F1: All sales were effected pursuant to a Rule 10b5-1 plan. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $58.34 · Expires 2030-04-01 | Direct | 70,399 |
Reported balance
After 2022-08-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-08-03 · Exercise / conversion · Disposed 70,398 · Balance 70,399 F2: The number of shares subject to the option were calculated using a 30-day average price. F3: Option became exercisable in four equal annual installments, commencing 4/1/2021. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $54.19 · Expires 2029-04-01 | Direct | 20,201 |
Reported balance
After 2022-08-03 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-08-03 · Exercise / conversion · Disposed 50,501 · Balance 20,201 F4: Option became exercisable in four equal annual installments, commencing 4/1/2020. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $62.21 · Expires 2025-04-01 | Direct | 0 |
Reported balance
After 2022-08-04 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-08-04 · Exercise / conversion · Disposed 22,541 · Balance 0 F5: Option became exercisable in four equal annual installments, commencing 4/1/2019. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $104.82 · Expires 2023-04-01 | Direct | 27,395 |
Reported balance
Holding disclosure · report date 2022-08-03 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 27,395 F8: Option became exercisable in four equal annual installments, commencing 4/1/2017. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $78.05 · Expires 2024-04-03 | Direct | 32,911 |
Reported balance
Holding disclosure · report date 2022-08-03 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 32,911 F9: Option became exercisable in four equal annual installments, commencing 4/3/2018. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $74.30 · Expires 2031-04-01 | Direct | 120,940 |
Reported balance
Holding disclosure · report date 2022-08-03 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 120,940 F10: Option became exercisable in four equal annual installments, commencing 4/1/2022. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $101.09 · Expires 2032-04-01 | Direct | 77,962 |
Reported balance
Holding disclosure · report date 2022-08-03 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance 77,962 F11: Option becomes exercisable in four equal annual installments, commencing 4/1/2023. |
| Common StockSEC Table I · non-derivative | IndirectBy Children's Trusts | 492 |
Reported balance
Holding disclosure · report date 2022-08-03 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 492 |
| Common Stock (restricted)SEC Table I · non-derivative | Direct | 5,827 |
Reported balance
Holding disclosure · report date 2022-08-03 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 5,827 |
| Stock UnitSEC Table I · non-derivative | Direct | 30,176.6725 |
Reported balance
Holding disclosure · report date 2022-08-03 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 30,176.6725 |
| Phantom Stock CreditsSEC Table II · derivative / convertible security · Conversion / exercise price $1.00 | Direct | 554.276 |
Reported balance
Holding disclosure · report date 2022-08-03 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 554.276 F6: Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person. F7: Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: All sales were effected pursuant to a Rule 10b5-1 plan.
F2: The number of shares subject to the option were calculated using a 30-day average price.
F3: Option became exercisable in four equal annual installments, commencing 4/1/2021.
F4: Option became exercisable in four equal annual installments, commencing 4/1/2020.
F5: Option became exercisable in four equal annual installments, commencing 4/1/2019.
F6: Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
F7: Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
F8: Option became exercisable in four equal annual installments, commencing 4/1/2017.
F9: Option became exercisable in four equal annual installments, commencing 4/3/2018.
F10: Option became exercisable in four equal annual installments, commencing 4/1/2022.
F11: Option becomes exercisable in four equal annual installments, commencing 4/1/2023.
PROKIDNEY CORP.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.81 · Expires 2036-05-28 | Direct | 135,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 135,000 · Balance 135,000 F1: These options were granted under the Issuer's non-employee director compensation policy. F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were granted under the Issuer's non-employee director compensation policy.
F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2026 Filed May 29, 2026 20:07 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantDirector stock option (right to buy) · Derivative | 135,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001193125-26-248262 · ownership.xml · derivative · entry 1 Lotvin Alan · CIK 0001472795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Class A Common Stock · 135,000 shares Expires 2036-05-28 F1 · shares: These options were granted under the Issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:12 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantDirector stock option (right to buy) · Derivative | 125,862 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0000950170-25-080260 · ownership.xml · derivative · entry 1 Lotvin Alan · CIK 0001472795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,862 Underlying: Class A Ordinary Shares · 125,862 shares Expires 2035-05-29 F1 · shares: These options were granted under the Issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:31 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantDirector stock option (right to buy) · Derivative | 62,558 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0000950170-24-068034 · ownership.xml · derivative · entry 1 Lotvin Alan · CIK 0001472795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,558 Underlying: Class A Ordinary Shares · 62,558 shares Expires 2034-05-30 F1 · shares: These options were granted under the Issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 13:16 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantDirector stock option (right to buy) · Derivative | 48,128 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0001209191-23-040422 · doc4.xml · derivative · entry 1 Lotvin Alan · CIK 0001472795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,128 Underlying: Class A Ordinary Shares · 48,128 shares Expires 2033-06-29 F1 · shares: These options were granted under the Issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:50 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 22,541 | $0.00 Strike: $62.21 | $0.00 |
DisclosureSEC source: 0001127602-22-020596 · form4.xml · derivative · entry 12 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,541 shares Expires 2025-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Option became exercisable in four equal annual installments, commencing 4/1/2019. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:50 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 22,541 | $104.00 | $2,344,264.00 |
DisclosureSEC source: 0001127602-22-020596 · form4.xml · nonDerivative · entry 6 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,183.3689 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:50 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 22,541 | $62.21 | $1,402,275.61 |
DisclosureSEC source: 0001127602-22-020596 · form4.xml · nonDerivative · entry 5 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,724.3689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:50 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 50,501 | $0.00 Strike: $54.19 | $0.00 |
DisclosureSEC source: 0001127602-22-020596 · form4.xml · derivative · entry 11 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,201 Underlying: Common Stock · 50,501 shares Expires 2029-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option became exercisable in four equal annual installments, commencing 4/1/2020. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:50 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 70,398 | $0.00 Strike: $58.34 | $0.00 |
DisclosureSEC source: 0001127602-22-020596 · form4.xml · derivative · entry 10 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,399 Underlying: Common Stock · 70,398 shares Expires 2030-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The number of shares subject to the option were calculated using a 30-day average price. F3 · derivative.exercise_date: Option became exercisable in four equal annual installments, commencing 4/1/2021. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:50 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 50,501 | $98.00 | $4,949,098.00 |
DisclosureSEC source: 0001127602-22-020596 · form4.xml · nonDerivative · entry 4 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,183.3689 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:50 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 50,501 | $54.19 | $2,736,649.19 |
DisclosureSEC source: 0001127602-22-020596 · form4.xml · nonDerivative · entry 3 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,684.3689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:50 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 70,398 | $98.00 | $6,899,004.00 |
DisclosureSEC source: 0001127602-22-020596 · form4.xml · nonDerivative · entry 2 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,183.3689 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:50 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 70,398 | $58.34 | $4,107,019.32 |
DisclosureSEC source: 0001127602-22-020596 · form4.xml · nonDerivative · entry 1 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,581.3689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2022 Filed Jul 14, 2022 01:29 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantCommon Units in ProKidney LP · Derivative | 1,514,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-012369 · dp177038_4-lotvin.xml · derivative · entry 2 Lotvin Alan · CIK 0001472795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,514,326 Underlying: Class A Ordinary Shares · 1,514,326 shares Expires not disclosed F3 · security: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis. F3 · derivative.exercise_price: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis. F4 · derivative.exercise_price: These 1,350,469 Common Units and 163,857 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2025. The Common Units and the PMEL RCUs do not expire. F4 · derivative.exercise_date: These 1,350,469 Common Units and 163,857 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2025. The Common Units and the PMEL RCUs do not expire. F4 · derivative.expiration_date: These 1,350,469 Common Units and 163,857 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2025. The Common Units and the PMEL RCUs do not expire. Read SEC document |
| July 11, 2022 Filed Jul 14, 2022 01:29 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantClass B Ordinary Shares · Derivative | 1,514,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-012369 · dp177038_4-lotvin.xml · derivative · entry 1 Lotvin Alan · CIK 0001472795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,514,326 Underlying: Class A Ordinary Shares · 1,514,326 shares Expires not disclosed F1 · derivative.exercise_price: Each Class B Ordinary Share has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP ("ProKidney") (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis. F2 · derivative.exercise_price: These 1,350,469 Class B Ordinary Shares and 163,857 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2025, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire. F2 · derivative.exercise_date: These 1,350,469 Class B Ordinary Shares and 163,857 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2025, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire. F2 · derivative.expiration_date: These 1,350,469 Class B Ordinary Shares and 163,857 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2025, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 23:28 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 77,962 | $101.09 Strike: $101.09 | $7,881,178.58 |
DisclosureSEC source: 0001127602-22-011636 · form4.xml · derivative · entry 4 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,962 Underlying: Common Stock · 77,962 shares Expires 2032-04-01 F2 · derivative.exercise_date: Option becomes exercisable in four equal installments, commencing 4/1/2023. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 23:28 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 38,129 | $101.09 | $3,854,460.61 |
DisclosureSEC source: 0001127602-22-011636 · form4.xml · nonDerivative · entry 1 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,183.3689 F1 · shares: Surrender of shares in payment of taxes due upon the vesting and settlement of PSUs on April 1, 2022. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:26 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock | 85,971 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006291 · form4.xml · nonDerivative · entry 1 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,312.3689 F1 · shares: Represents shares earned by the reporting person pursuant to certain performance stock units (the "PSUs"), which were granted to the reporting person under the Issuer's 2017 Incentive Compensation Plan on June 5, 2019. The PSUs were earned based on the attainment of certain performance metrics, which performance metrics were certified by the Management and Planning Committee of the Board of Directors of the Issuer on February 21, 2022. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:20 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 21,386 | $0.00 Strike: $102.26 | $0.00 |
DisclosureSEC source: 0001127602-22-002958 · form4.xml · derivative · entry 6 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,386 shares Expires 2022-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option became exercisable in four equal annual installments, commencing 4/1/2016. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:20 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 21,386 | $106.50 | $2,277,566.23 |
DisclosureSEC source: 0001127602-22-002958 · form4.xml · nonDerivative · entry 2 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,341.3689 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:20 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 21,386 | $102.26 | $2,186,932.36 |
DisclosureSEC source: 0001127602-22-002958 · form4.xml · nonDerivative · entry 1 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,727.3689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 22:04 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock (restricted) | 200 | $88.78 | $17,756.00 |
DisclosureSEC source: 0001127602-21-031962 · form4.xml · nonDerivative · entry 1 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,827 F1 · kind: Transaction represents the withholding of shares by the Issuer to satisfy FICA taxes arising from the reporting person being retirement eligible. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 21:43 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 2,781 | $83.67 | $232,686.27 |
DisclosureSEC source: 0001127602-21-020816 · form4.xml · nonDerivative · entry 1 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,047.6756 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. Read SEC document |
| April 03, 2021 Filed Apr 5, 2021 21:38 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 1,705 | $74.30 | $126,681.50 |
DisclosureSEC source: 0001127602-21-013214 · form4.xml · nonDerivative · entry 1 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,828.6756 F1 · shares: Surrender of shares in payment of taxes due upon the vesting and settlement of a restricted stock unit award on April 3, 2021. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:16 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 120,940 | $74.30 Strike: $74.30 | $8,985,842.00 |
DisclosureSEC source: 0001127602-21-012762 · form4.xml · derivative · entry 6 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,940 Underlying: Common Stock · 120,940 shares Expires 2031-04-01 F3 · derivative.exercise_date: Option becomes exercisable in four equal installments, commencing 4/1/2022. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:16 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 42,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-012762 · form4.xml · nonDerivative · entry 2 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,690.6756 F2 · shares: Surrender of shares in payment of taxes due upon the vesting and settlement of the PSUs on April 1, 2021. Read SEC document |
| February 01, 2021 Filed Apr 2, 2021 21:16 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock | 95,669 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-012762 · form4.xml · nonDerivative · entry 1 Lotvin Alan · CIK 0001472795 · EVP&President-PharmacyServices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,121.6756 F1 · shares: Represents shares earned by the reporting person pursuant to certain performance stock units (the "PSUs"), which were granted to the reporting person under the Issuer's 2017 Incentive Compensation Plan on February 1, 2021. The PSUs were earned based on the attainment of certain performance metrics, which performance metrics were certified by the Management and Planning Committee of the Board of Directors of the Issuer on February 1, 2021. The PSUs vested and settled on April 1, 2021. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 22:43 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 15,736 | $0.00 Strike: $74.29 | $0.00 |
DisclosureSEC source: 0001127602-21-001522 · form4.xml · derivative · entry 8 Lotvin Alan · CIK 0001472795 · EVP and President-CVS Caremark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,736 shares Expires 2021-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Remaining options became exercisable in four equal annual installments beginning on 4/1/2015. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 22:43 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 10,100 | $0.00 Strike: $54.19 | $0.00 |
DisclosureSEC source: 0001127602-21-001522 · form4.xml · derivative · entry 7 Lotvin Alan · CIK 0001472795 · EVP and President-CVS Caremark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,702 Underlying: Common Stock · 10,100 shares Expires 2029-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option became exercisable in four equal annual installments, commencing 4/1/2020. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 22:43 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 25,836 | $75.00 | $1,937,700.00 |
DisclosureSEC source: 0001127602-21-001522 · form4.xml · nonDerivative · entry 3 Lotvin Alan · CIK 0001472795 · EVP and President-CVS Caremark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,368.6799 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 Trading Plan. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 22:43 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 15,736 | $74.29 | $1,169,027.44 |
DisclosureSEC source: 0001127602-21-001522 · form4.xml · nonDerivative · entry 2 Lotvin Alan · CIK 0001472795 · EVP and President-CVS Caremark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,204.6799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 22:43 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 10,100 | $54.19 | $547,319.00 |
DisclosureSEC source: 0001127602-21-001522 · form4.xml · nonDerivative · entry 1 Lotvin Alan · CIK 0001472795 · EVP and President-CVS Caremark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,468.6799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 21:22 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 7,138 | $70.00 | $499,660.00 |
DisclosureSEC source: 0001127602-20-029248 · form4.xml · nonDerivative · entry 1 Lotvin Alan · CIK 0001472795 · EVP and President-CVS Caremark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,023.3273 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. Read SEC document |
| May 11, 2020 Filed May 13, 2020 13:08 UTC | CVS HEALTH Corp CVS · Entity 2884 | PurchaseCommon Stock | 5,000 | $63.14 | $315,675.00 |
DisclosureSEC source: 0001127602-20-016337 · form4.xml · nonDerivative · entry 1 Lotvin Alan · CIK 0001472795 · EVP and President-CVS Caremark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,161.3273 Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:32 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 140,797 | $58.61 Strike: $58.61 | $8,252,112.17 |
DisclosureSEC source: 0001127602-20-013234 · form4.xml · derivative · entry 5 Lotvin Alan · CIK 0001472795 · EVP, Transformation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,797 Underlying: Common Stock · 140,797 shares Expires 2030-04-01 F2 · derivative.exercise_price: The number of shares subject to the option were calculated using a 30-day average price. F3 · derivative.exercise_date: Option becomes exercisable in four equal annual installments, commencing 4/1/2021. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:32 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 1,481 | $58.34 | $86,401.54 |
DisclosureSEC source: 0001127602-20-013234 · form4.xml · nonDerivative · entry 1 Lotvin Alan · CIK 0001472795 · EVP, Transformation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,161.3273 F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a restricted stock award. Read SEC document |
| April 01, 2020 Filed Apr 7, 2020 21:39 UTC Amendment | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 140,797 | $0.00 Strike: $58.34 | $0.00 |
DisclosureSEC source: 0001127602-20-013410 · form4a.xml · derivative · entry 1 Lotvin Alan · CIK 0001472795 · EVP, Transformation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,797 Underlying: Common Stock · 140,797 shares Expires 2030-04-01 F1 · derivative.exercise_price: This Form 4/A is being filed in order to correct the exercise price (Table II, column 2) for the stock option granted on 4/1/2020, which was reported incorrectly on the original Form 4 due to a clerical error. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:41 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Unit | 11,828 | $59.18 | $699,981.04 |
DisclosureSEC source: 0001127602-20-009164 · form4.xml · nonDerivative · entry 2 Lotvin Alan · CIK 0001472795 · EVP, Transformation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,945.094 F2 · shares: Consists of Stock Units Awarded at market price pursuant to Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan, the receipt of which the reporting person has elected to defer. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:41 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 160 | $59.18 | $9,468.80 |
DisclosureSEC source: 0001127602-20-009164 · form4.xml · nonDerivative · entry 1 Lotvin Alan · CIK 0001472795 · EVP, Transformation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,303.3273 F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a restricted stock award. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:58 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 80,802 | $54.19 Strike: $54.19 | $4,378,660.38 |
DisclosureSEC source: 0001127602-19-014675 · form4.xml · derivative · entry 5 Lotvin Alan · CIK 0001472795 · EVP, Transformation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,802 Underlying: Common Stock · 80,802 shares Expires 2029-04-01 F2 · derivative.exercise_date: Option becomes exercisable in four equal annual installments, commencing 4/1/2020. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:58 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 863 | $54.19 | $46,765.97 |
DisclosureSEC source: 0001127602-19-014675 · form4.xml · nonDerivative · entry 1 Lotvin Alan · CIK 0001472795 · EVP, Transformation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,578.2742 F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a stock award under an incentive compensation plan. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:48 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Unit | 6,342 | $57.83 | $366,757.86 |
DisclosureSEC source: 0001127602-19-009279 · form4.xml · nonDerivative · entry 2 Lotvin Alan · CIK 0001472795 · EVP, Transformation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,141.1519 F2 · shares: Consists of Stock Units awarded at market price pursuant to Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan, the receipt of which the reporting person has elected to defer. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:48 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 292 | $57.83 | $16,886.36 |
DisclosureSEC source: 0001127602-19-009279 · form4.xml · nonDerivative · entry 1 Lotvin Alan · CIK 0001472795 · EVP, Transformation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,508.2742 F1 · shares: SurreSurrender of shares in payment of withholding taxes due upon the vesting of restricted stock awards under the Issuer's 2017 Incentive Compensation Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.